Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus pembrolizumab and carboplatin versus standard of care for recurrent/metastatic head and neck squamous cell carcinoma
ISRCTN13351736Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Pembrolizumab + Amivantamab + Carboplatin with Pembrolizumab + 5-fluorouracil + Carboplatin or Cisplatin (2 arms). Primary endpoints: Overall survival and Objective response rate by blinded independent central review. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN13351736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13351736.